Nexell: Absturz warum? - 500 Beiträge pro Seite

[hannah6]

Kennt jemand von euch die Neuigkeiten, die zum Absturz geführt haben?

grüße
hannah

[Sugar2000]

Das würde ich auch gerne wissen!
Wenn die nicht konkurs sind würde ich gerne einsteigen!
;-)
Sugar

[Sugar2000]

Nexell Therapeutics Announces Year End 2001 Results and Recent Developments
IRVINE, Calif.--(BW HealthWire)--March 28, 2002--


Operating Loss Declines by 28%; Cash Used in Operations Decreases by $13.5 Million

Nexell Therapeutics Inc. (Nasdaq:NEXL) announced today its results for the year ended December 31, 2001.

Company Seeks to Stabilize Financial Condition of New Therapeutics
Development Business


Since the third quarter of 2001, Nexell has executed and implemented agreements to transfer sales, marketing and distribution of its former Toolbox business to Baxter Healthcare Corp. ("Baxter"). These changes have enabled the Company to reduce ongoing staffing and expenses as it focuses on development of selected therapeutic applications of its stem cell and cell processing technology. Substantially all of the Company`s product revenue was also eliminated as a result of this transaction. During this transition, the Company is exploring both financing and strategic business combinations with the intention of strengthening its financial condition but no such transactions have been entered into as of this date.

Nexell`s cash and cash equivalents are insufficient to fund projected operating expenses through the current fiscal year and, based on the Company`s current projections, will not fund operations beyond June 2002. An effort to raise funds through a private placement of equity securities was terminated in the first quarter of 2002 principally so that the Company could focus efforts on potential business combinations. Any such transactions could result in substantial dilution to common shareholders.

In addition, in order to complete such transactions, it may be necessary to simplify the Company`s capital structure by converting its existing two series of preferred stock to common stock, thereby eliminating the liquidation preference of such preferred stock. In such an event it is possible that in connection with the conversion of the Series B Preferred Stock, Baxter could own substantially in excess of a majority of the outstanding common stock.

"We believe that we have successfully refocused the Company`s business strategy and research and development operations," said William A. Albright, Jr., President and Chief Executive Officer of Nexell. "We continue to actively pursue all strategic options to strengthen our financial condition and enable the Company to continue its therapeutic development objectives."

Liquidity


Cash and cash equivalents at December 31, 2001, were $5.1 million versus $12.1 million at December 31, 2000.

Because of the Company`s recurring losses from operations, negative cash flow from operations and need for continued funding the independent auditors` report on the consolidated financial statements for the year ended December 31, 2001, contains an explanatory paragraph indicating there is substantial doubt about the Company`s ability to continue as a going concern. The Company is analyzing and considering various financial, strategic and restructuring alternatives available to the Company, including a strategic alliance, the possible sale of all or a portion of the Company or liquidation.

2001 Operating Results


All financial results were impacted significantly by the Baxter transaction, which was completed as of August 31, 2001. For the year ended December 31, 2001, total revenues decreased $5.0 million, or 28 percent, to $13.2 million, compared to $18.2 million in 2000. In accordance with the terms of the asset purchase agreement, Baxter paid Nexell approximately $2.6 million at closing. Additional proceeds of approximately $2.1 million were received in March 2002 as a result of a final settlement agreement between the parties executed in March 2002 resolving certain post-closing adjustments and related matters. The proceeds were partially offset by approximately $0.7 million in net cash collected by the Company related to activities during the four months following the transaction. In addition, Baxter agreed to purchase additional inventory and reimburse Nexell for certain transitional support services in the first quarter of 2002 with such additional proceeds totaling $1.6 million received in the first quarter of 2002. Certain non-recurring charges were recorded in the third and fourth quarters as described below as a result of the agreement with Baxter and the related restructure.

Gross profit on sales in fiscal 2001 decreased to $6.4 million from $6.8 million, a decrease of $0.4 million or 6 percent. The gross profit percentage in 2001 was 48 percent versus 37 percent in 2000. These changes were the result of the transfer of the cell processing product business to Baxter, changes in sales mix, principally decreased sales of lower margin devices and certain non-recurring items between years.

Operating expenses in 2001 were $29.6 million compared to $39.2 million in 2000, a decrease of $9.6 million or 25 percent. This was the result of focused headcount reductions, including the elimination of sales and marketing functions, as a result of the Company`s shift in focus to cellular drug development, which included the transfer of its cell processing product business to Baxter.

The Company incurred non-operating expense of $0.1 million in 2001 compared to non-operating income of $4.4 million realized in 2000. Factors in this difference were that in 2000 the Company realized a non-operating gain of $3.2 million on the sale of an equity investment and interest income declined by approximately $0.8 million in 2001 due to lower average cash balances.

The net loss for fiscal 2001 declined by $4.8 million, or 17 percent, to $23.3 million from the 2000 net loss of $28.1 million. The net loss applicable to common stock also declined in 2001 to $30.0 million or $1.45 per share, versus $34.5 million or $1.84 per share, in 2000. Weighted average shares outstanding for the year ended December 31, 2001, were 20.7 million versus 18.8 million for the comparable 2000 period.

Fourth Quarter Results


Nexell Therapeutics reported fourth quarter 2001 revenue of $0.2 million, a $3.1 million decrease in revenue from the third quarter of 2001. Comparing the same period in the previous year, fourth quarter 2000 revenues were $4.3 million or $4.1 million higher than the same period in 2001. These decreases resulted from the transfer of the cell processing products business to Baxter. In the fourth quarter of 2001, the Company recognized gross profit of $1.9 million. This was principally the result of the reversal of previous recognized cost of goods sold as a result of the final settlement with Baxter. In the previous quarter the Company had recorded a $1.2 million increase to cost of goods sold. This was a result of Baxter`s decision at that time not to purchase certain inventory that the Company believed would have been saleable in the ordinary course of business except for the non compete provisions that were part of the agreement with Baxter.

Operating expenses for the fourth quarter 2001 were $4.8 million, compared to $7.8 million for the same period in 2000. This decrease occurred despite the inclusion of a $1.3 million charge in 2001 for the write-down of certain fixed assets held for sale as a result of changes in the business. The decrease is primarily due to the implementation of spending reductions and the transaction with Baxter, which resulted in the elimination of sales and marketing expenses. The net loss for the fourth quarter of 2001 decreased $3.6 million to $3.0 million from a loss of $6.6 million in the comparable quarter in 2000. Net loss applicable to common stock for the fourth quarter of 2001 was $4.7 million or $0.23 per share versus a net loss of $8.2 million, or $0.43 per share in the fourth quarter of 2000.

Fourth Quarter Developments


In November 2001 the Company announced that it had received Orphan Drug Designation for its lead therapeutic stem cell product for the treatment of chronic granulomatous disease (CGD).

In December 2001, Joseph A. Mollica resigned his position as a Director of the Company due to his commitments as Chairman, Chief Executive Officer and President of Pharmacopeia, Inc.

Nexell Therapeutics Inc.


Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq: NEXL) is a biotechnology company that is focused on the modification or enhancement of human immune function and blood cell formation utilizing adult hematopoietic (blood-forming) stem cells and other specially prepared cell populations. Nexell is developing proprietary cell-based therapies that address major unmet medical needs, including treatments for genetic blood disorders, autoimmune diseases, and cancer.

This release contains forward-looking statements which statements are subject to certain risks and uncertainties that could cause actual results to differ materially from current expectations. Such risks and uncertainties include: the Company`s ability to continue as a going concern; market demand for cell processing products; marketing and sales of cell processing products by Baxter; the Company`s need for additional capital; effect of the August 2001 Baxter transaction on the Company`s operating expenses; the ability of the Company to maintain its listing of its publicly traded securities on Nasdaq; whether the Company will be able to enter into any business combination transactions; the potential substantial dilution to Common stockholders in the event the Company`s two series of Preferred Stock are converted to Common Stock; and any additional factors described from time to time in the Company`s filings with the SEC. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims any intent or obligation to update these forward-looking statements.

Dollar figures and percentages in this release are approximated numbers.

Note to Investors and Editors: Nexell Therapeutics Inc. press releases are available on the Internet through www.nexell.com and through Business Wire`s web site at http://www.businesswire.com. The releases are also available at no charge through Business Wire`s fax-on-demand service at 800/411-8792.

NEXELL THERAPEUTICS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share data)


Three months ended Year ended December 31
December 31

2001 2000 2001 2000

Revenue $ 150 $ 4,268 $ 13,180 $ 18,180
Cost of
goods sold (1,738) 3,441 6,813 11,429

Gross profit 1,888 827 6,367 6,751

Costs and expenses:
Research and
development 619 2,137 5,919 10,828
Selling, general and
administrative 2,829 3,519 14,347 20,911
Depreciation
and amortization 1,375 2,081 6,711 7,504
Impairment of
intangible assets 0 0 2,637 0

Total operating
expenses 4,823 7,737 29,614 39,243

Operating loss (2,935) (6,910) (23,247) (32,492)
Other (income)
expense, net 67 (292) 63 (4,397)

Net loss (3,002) (6,618) (23,310) (28,095)
Preferred
stock dividends (1,679) (1,622) (6,640) (6,371)

Net loss
applicable to
common stock $(4,681) $(8,240) $(29,950) $(34,466)

Basic and
diluted loss
per share $ (0.23) $ (0.43) $ (1.45) $ (1.84)

Weighted average
number of shares of
common stock
outstanding - basic
and diluted
(in millions) 20.9 19.1 20.7 18.8

Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)

December 31, December 31,
2001 2000

Assets
Cash and cash
equivalents $ 5,092 $ 12,119
Inventory -
finished goods 286 3,831
Fixed assets, net 1,625 8,164
Intangible assets, net 32,737 39,372
Other assets 4,774 11,969

Total assets $ 44,514 $ 75,455

Liabilities and stockholders` equity
Current liabilities $ 5,139 $ 10,528
Capital lease obligation
non-current portion -- 1,912
Deferred revenue,
non-current portion 1,125 1,575
Stockholders` equity 38,250 61,440

Total liabilities and
stockholders` equity $ 44,514 $ 75,455

CONTACT: Nexell Therapeutics Inc., Irvine
William A. Albright, Jr. or Wayne A. Tyo, 949/470-9011
[e-mail]

Copyright 2002, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire`s members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

[Sugar2000]

und noch was.....

Nexell Therapeutics 4th Quarter Loss 23 Cents/Share



Nexell Therapeutics Inc. - Irvine, Calif.
4th Quar Dec. 31:
2001 2000
Revenue $150,000 $4,268,000
Net income (3,002,000) (6,618,000)
Avg shrs 20,900,000 19,100,000
Shr earns
Net income (.23) (.43)



Figures in parentheses are losses.
Since the third quarter, Nexell Therapeutics Inc. (NEXL) has implemented agreements to transfer sales, marketing and distribution of its former Toolbox business to Baxter Healthcare Corp. Substantially all product revenue was eliminated as a result of that transaction.

The biotechnology firm said its cash and equivalents won`t fund operating expenses beyond June.

The biotechnology firm ended 2001 with $5.1 million in cash and cash equivalents, down 58% from $12.1 million a year earlier.

Nexell`s auditors report indicates that there is substantial doubt about the company`s ability to continue as a going concern, due to recurring losses from operations, negative cash flow from operations and the need for additional funding. The company is considering alternatives, including a strategic alliance, the possible sale of some or all of the company or liquidation.

(This story was originally published by Dow Jones Newswires)




Copyright (c) 2002 Dow Jones & Company, Inc.
All Rights Reserved

[WhiteRabbit]

Das Jahresergebnis 2001:

Thursday March 28, 7:37 am Eastern Time
Press Release
SOURCE: Nexell Therapeutics Inc.
Nexell Therapeutics Announces Year End 2001 Results and Recent Developments
Operating Loss Declines by 28%; Cash Used in Operations Decreases by $13.5 Million
IRVINE, Calif.--(BW HealthWire)--March 28, 2002-- Nexell Therapeutics Inc. (Nasdaq:NEXL - news) announced today its results for the year ended December 31, 2001.


Company Seeks to Stabilize Financial Condition of New Therapeutics
Development Business

Since the third quarter of 2001, Nexell has executed and implemented agreements to transfer sales, marketing and distribution of its former Toolbox business to Baxter Healthcare Corp. (``Baxter``). These changes have enabled the Company to reduce ongoing staffing and expenses as it focuses on development of selected therapeutic applications of its stem cell and cell processing technology. Substantially all of the Company`s product revenue was also eliminated as a result of this transaction. During this transition, the Company is exploring both financing and strategic business combinations with the intention of strengthening its financial condition but no such transactions have been entered into as of this date.

Nexell`s cash and cash equivalents are insufficient to fund projected operating expenses through the current fiscal year and, based on the Company`s current projections, will not fund operations beyond June 2002. An effort to raise funds through a private placement of equity securities was terminated in the first quarter of 2002 principally so that the Company could focus efforts on potential business combinations. Any such transactions could result in substantial dilution to common shareholders.

In addition, in order to complete such transactions, it may be necessary to simplify the Company`s capital structure by converting its existing two series of preferred stock to common stock, thereby eliminating the liquidation preference of such preferred stock. In such an event it is possible that in connection with the conversion of the Series B Preferred Stock, Baxter could own substantially in excess of a majority of the outstanding common stock.

``We believe that we have successfully refocused the Company`s business strategy and research and development operations,`` said William A. Albright, Jr., President and Chief Executive Officer of Nexell. ``We continue to actively pursue all strategic options to strengthen our financial condition and enable the Company to continue its therapeutic development objectives.``

Liquidity

Cash and cash equivalents at December 31, 2001, were $5.1 million versus $12.1 million at December 31, 2000.

Because of the Company`s recurring losses from operations, negative cash flow from operations and need for continued funding the independent auditors` report on the consolidated financial statements for the year ended December 31, 2001, contains an explanatory paragraph indicating there is substantial doubt about the Company`s ability to continue as a going concern. The Company is analyzing and considering various financial, strategic and restructuring alternatives available to the Company, including a strategic alliance, the possible sale of all or a portion of the Company or liquidation.

2001 Operating Results

All financial results were impacted significantly by the Baxter transaction, which was completed as of August 31, 2001. For the year ended December 31, 2001, total revenues decreased $5.0 million, or 28 percent, to $13.2 million, compared to $18.2 million in 2000. In accordance with the terms of the asset purchase agreement, Baxter paid Nexell approximately $2.6 million at closing. Additional proceeds of approximately $2.1 million were received in March 2002 as a result of a final settlement agreement between the parties executed in March 2002 resolving certain post-closing adjustments and related matters. The proceeds were partially offset by approximately $0.7 million in net cash collected by the Company related to activities during the four months following the transaction. In addition, Baxter agreed to purchase additional inventory and reimburse Nexell for certain transitional support services in the first quarter of 2002 with such additional proceeds totaling $1.6 million received in the first quarter of 2002. Certain non-recurring charges were recorded in the third and fourth quarters as described below as a result of the agreement with Baxter and the related restructure.

Gross profit on sales in fiscal 2001 decreased to $6.4 million from $6.8 million, a decrease of $0.4 million or 6 percent. The gross profit percentage in 2001 was 48 percent versus 37 percent in 2000. These changes were the result of the transfer of the cell processing product business to Baxter, changes in sales mix, principally decreased sales of lower margin devices and certain non-recurring items between years.

Operating expenses in 2001 were $29.6 million compared to $39.2 million in 2000, a decrease of $9.6 million or 25 percent. This was the result of focused headcount reductions, including the elimination of sales and marketing functions, as a result of the Company`s shift in focus to cellular drug development, which included the transfer of its cell processing product business to Baxter.

The Company incurred non-operating expense of $0.1 million in 2001 compared to non-operating income of $4.4 million realized in 2000. Factors in this difference were that in 2000 the Company realized a non-operating gain of $3.2 million on the sale of an equity investment and interest income declined by approximately $0.8 million in 2001 due to lower average cash balances.

The net loss for fiscal 2001 declined by $4.8 million, or 17 percent, to $23.3 million from the 2000 net loss of $28.1 million. The net loss applicable to common stock also declined in 2001 to $30.0 million or $1.45 per share, versus $34.5 million or $1.84 per share, in 2000. Weighted average shares outstanding for the year ended December 31, 2001, were 20.7 million versus 18.8 million for the comparable 2000 period.

Fourth Quarter Results

Nexell Therapeutics reported fourth quarter 2001 revenue of $0.2 million, a $3.1 million decrease in revenue from the third quarter of 2001. Comparing the same period in the previous year, fourth quarter 2000 revenues were $4.3 million or $4.1 million higher than the same period in 2001. These decreases resulted from the transfer of the cell processing products business to Baxter. In the fourth quarter of 2001, the Company recognized gross profit of $1.9 million. This was principally the result of the reversal of previous recognized cost of goods sold as a result of the final settlement with Baxter. In the previous quarter the Company had recorded a $1.2 million increase to cost of goods sold. This was a result of Baxter`s decision at that time not to purchase certain inventory that the Company believed would have been saleable in the ordinary course of business except for the non compete provisions that were part of the agreement with Baxter.

Operating expenses for the fourth quarter 2001 were $4.8 million, compared to $7.8 million for the same period in 2000. This decrease occurred despite the inclusion of a $1.3 million charge in 2001 for the write-down of certain fixed assets held for sale as a result of changes in the business. The decrease is primarily due to the implementation of spending reductions and the transaction with Baxter, which resulted in the elimination of sales and marketing expenses. The net loss for the fourth quarter of 2001 decreased $3.6 million to $3.0 million from a loss of $6.6 million in the comparable quarter in 2000. Net loss applicable to common stock for the fourth quarter of 2001 was $4.7 million or $0.23 per share versus a net loss of $8.2 million, or $0.43 per share in the fourth quarter of 2000.

Fourth Quarter Developments

In November 2001 the Company announced that it had received Orphan Drug Designation for its lead therapeutic stem cell product for the treatment of chronic granulomatous disease (CGD).

In December 2001, Joseph A. Mollica resigned his position as a Director of the Company due to his commitments as Chairman, Chief Executive Officer and President of Pharmacopeia, Inc.

Nexell Therapeutics Inc.

Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq: NEXL - news) is a biotechnology company that is focused on the modification or enhancement of human immune function and blood cell formation utilizing adult hematopoietic (blood-forming) stem cells and other specially prepared cell populations. Nexell is developing proprietary cell-based therapies that address major unmet medical needs, including treatments for genetic blood disorders, autoimmune diseases, and cancer.

This release contains forward-looking statements which statements are subject to certain risks and uncertainties that could cause actual results to differ materially from current expectations. Such risks and uncertainties include: the Company`s ability to continue as a going concern; market demand for cell processing products; marketing and sales of cell processing products by Baxter; the Company`s need for additional capital; effect of the August 2001 Baxter transaction on the Company`s operating expenses; the ability of the Company to maintain its listing of its publicly traded securities on Nasdaq; whether the Company will be able to enter into any business combination transactions; the potential substantial dilution to Common stockholders in the event the Company`s two series of Preferred Stock are converted to Common Stock; and any additional factors described from time to time in the Company`s filings with the SEC. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims any intent or obligation to update these forward-looking statements.

Dollar figures and percentages in this release are approximated numbers.

Note to Investors and Editors: Nexell Therapeutics Inc. press releases are available on the Internet through www.nexell.com and through Business Wire`s web site at http://www.businesswire.com. The releases are also available at no charge through Business Wire`s fax-on-demand service at 800/411-8792.

NEXELL THERAPEUTICS INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands, except share and per share data)


Three months ended Year ended December 31
December 31
2001 2000 2001 2000

Revenue $ 150 $ 4,268 $ 13,180 $ 18,180
Cost of
goods sold (1,738) 3,441 6,813 11,429

Gross profit 1,888 827 6,367 6,751

Costs and expenses:
Research and
development 619 2,137 5,919 10,828
Selling, general and
administrative 2,829 3,519 14,347 20,911
Depreciation
and amortization 1,375 2,081 6,711 7,504
Impairment of
intangible assets 0 0 2,637 0

Total operating
expenses 4,823 7,737 29,614 39,243

Operating loss (2,935) (6,910) (23,247) (32,492)
Other (income)
expense, net 67 (292) 63 (4,397)

Net loss (3,002) (6,618) (23,310) (28,095)
Preferred
stock dividends (1,679) (1,622) (6,640) (6,371)

Net loss
applicable to
common stock $(4,681) $(8,240) $(29,950) $(34,466)

Basic and
diluted loss
per share $ (0.23) $ (0.43) $ (1.45) $ (1.84)

Weighted average
number of shares of
common stock
outstanding - basic
and diluted
(in millions) 20.9 19.1 20.7 18.8

Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)

December 31, December 31,
2001 2000

Assets
Cash and cash
equivalents $ 5,092 $ 12,119
Inventory -
finished goods 286 3,831
Fixed assets, net 1,625 8,164
Intangible assets, net 32,737 39,372
Other assets 4,774 11,969

Total assets $ 44,514 $ 75,455

Liabilities and stockholders` equity
Current liabilities $ 5,139 $ 10,528
Capital lease obligation
non-current portion -- 1,912
Deferred revenue,
non-current portion 1,125 1,575
Stockholders` equity 38,250 61,440

Total liabilities and
stockholders` equity $ 44,514 $ 75,455



--------------------------------------------------------------------------------
Contact:
Nexell Therapeutics Inc., Irvine
William A. Albright, Jr. or Wayne A. Tyo, 949/470-9011
[e-mail]

[SCHRODDI]

Habe Nexell zwar schon lange nicht mehr! Verkauft bei 2,60Euro.
Aber ich habe was gefunden, dass die Frage beantworten wird!


Nexell: Kapitalnot, Kurssturz
--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)

Die Aktien von Nexell Therapeutics brechen zuletzt um 58.33 Prozent auf 45 cents ein. Das Unternehmen berichtete mit dem vorbörslich präsentierten Quartalsergebnis, dass die Barbestände "nicht ausreichend" seien, um "die erwarteten operativen Kosten" nach Juni decken zu können. Der größte Teil des Umsatzes wurde durch den Transfer des Toolbox Geschäfts an Baxter Healthcare eliminiert, hieß es weiter. Die Gespräche mit Kreditgebern zeigten bisher kein zufriedenstellendes Ergebnis.

Nun ist das Unternehmen auf der Suche nach Partnern, die eine Geschäfts- oder Finanzkombination interessiert sind. Eine solche Zusammenlegung von Geschäftsteilen könnte - so die Warnung des Unternehmens - "substantiell Wert für die Aktionäre" mindern. Darüber hinaus beabsichtigt das Unternehmen, die ausstehenden Vorzugsaktien in Stammaktien umzuwandeln, um die Aktienstruktur zu vereinfachen.

Die Wirtschaftsprüfer teilten im Bericht für das Geschäftsjahr Ende Dezember 2001 mit, dass 5.1 Millionen Dollar ausreichend wären, dass Nexell seine Geschäfte weiterführen kann.